DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cough Variant Asthma

Phase: N/A

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Hong Jianguo, Professor, Principal Investigator, Affiliation: Shanghai Jiao Tong University Affiliated First People's Hospital,

Overall contact:
AstraZeneca China Clinical Study Information, Phone: +8621 52564555, Email: tracy.shi@AstraZeneca.com

Summary

This open label, non-interventional study is to show the efficacy of Pulmicort®Respules® in cough variant asthma in patient aged 5-year old or younger in outpatient department

Clinical Details

Official title: A Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Patient Aged 5-Year Old or Younger in Outpatient Department

Study design: Other, Prospective

Primary outcome: Patient Symptom Score

Secondary outcome:

Patient Compliance Report

Investigator Assessment Report

Eligibility

Minimum age: N/A. Maximum age: 5 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Provision of informed consent

- Patient who has been prescribed Pulmicort® Respules® according to physician's

judgement, irrespective of the inclusion in the study.

- The usage of Pulmicort® Respules® follows local authorised package insert.

Exclusion Criteria:

- Allergy to any ingredient of Pulmicort® Respules®

- With history of Leukotriene Modifier (LM) usage prior to 2 weeks of recruitment or

following plan.

- Have used systemic/inhaled steroid prior to 2 weeks of recruitment

Locations and Contacts

AstraZeneca China Clinical Study Information, Phone: +8621 52564555, Email: tracy.shi@AstraZeneca.com

Research Site, Chongqing, China; Not yet recruiting

Research Site, Shanghai, China; Not yet recruiting

Research Site, Hefei, Anhui, China; Not yet recruiting

Research Site, Fuzhou, Fujian, China; Not yet recruiting

Research Site, Guangzhou, Guangdong, China; Not yet recruiting

Research Site, Shenzhen, Guangdong, China; Not yet recruiting

Research Site, Xiamen, Guangdong, China; Not yet recruiting

Research Site, Zhongshan, Guangdong, China; Not yet recruiting

Research Site, Zhengzhou, Henan, China; Not yet recruiting

Research Site, Wuhan, Hubei, China; Not yet recruiting

Research Site, Changsha, Hunan, China; Not yet recruiting

Research Site, Nanjing, Jiangsu, China; Not yet recruiting

Research Site, Suzhou, Jiangsu, China; Not yet recruiting

Research Site, Wuxi, Jiangsu, China; Not yet recruiting

Research Site, Nanchang, Jiangxi, China; Not yet recruiting

Research Site, Jinan, Shandong, China; Not yet recruiting

Research Site, Qingdao, Shandong, China; Recruiting

Research Site, Taiyuan, Shanxi, China; Not yet recruiting

Research Site, Xi'an, Shanxi, China; Not yet recruiting

Research Site, Chengdu, Sichuan, China; Not yet recruiting

Research Site, Kunming, Yunnan, China; Not yet recruiting

Research Site, Hangzhou, Zhejiang, China; Not yet recruiting

Research Site, Ningbo, Zhejiang, China; Not yet recruiting

Research Site, Rui'an, Zhejiang, China; Not yet recruiting

Research Site, Wenzhou, Zhejiang, China; Not yet recruiting

Additional Information

Starting date: April 2008
Ending date: May 2009
Last updated: April 15, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008